Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06129747 · ClinicalTrials.gov registry record · Phase 2
Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast
A Phase 2 study of Breast Cancer and Tumor, Breast, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 2
- Study locations
NCT06129747 is a Phase 2 study of Breast Cancer and Tumor, Breast that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 55 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06129747, a Phase 2 study of Breast Cancer and Tumor, Breast, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 2
- Study locations
Study Summary
The standard treatment for participants whose cancer has returned after breast conserving surgery is radiation given twice daily (separated by at least 6 hours) for a total of 30 treatments. The purpose of this study is to find out if giving radiation once a day for 15 treatments after repeat breast conserving surgery works as well as giving it the standard way.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
Study Locations (2)
Ohio
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
- Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2023-11-30 |
| Est. Completion | 2029-08-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06129747
The ClinicalTrials.gov registry entry for NCT06129747 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Radiation Therapy is the first listed.
NCT06129747 reports 2 study locations spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06129747 about?
NCT06129747 is a clinical study titled "Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast". The standard treatment for participants whose cancer has returned after breast conserving surgery is radiation given twice daily (separated by at least 6 hours) for a total of 30 treatments. The purpose of this study is to find out if giving radiation once a day for 15 treatments after repeat breast...
What is the current status of trial NCT06129747?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2023-11-30. Estimated completion is 2029-08-09.
What conditions does trial NCT06129747 study?
This clinical trial studies the following conditions: Breast Cancer, Tumor, Breast.
What interventions are being tested in trial NCT06129747?
The interventions under investigation include: Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT06129747?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06129747 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.